文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

泌尿外科术中自体血回输的系统评价与荟萃分析

Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
PubMed 文献 · BJU Int · 2018-06-10

荟萃分析仅在前列腺切除术中可行,显示ICS较无血液保护技术降低异体输血率(OR 0.34,95%CI 0.15-0.76),但与术前自体献血(PAD)相比无差异(OR 0.76,95%CI 0.39-1.31)。肿瘤复发、并发症和成本因异质性未能荟萃分析,证据级别较低。

要点

  • 前列腺切除术中ICS较无血液保护技术降低异体输血率(OR 0.34,95%CI 0.15-0.76)。
  • ICS与术前自体献血(PAD)相比异体输血率无显著差异(OR 0.76,95%CI 0.39-1.31)。
  • ICS未增加前列腺切除术后肿瘤复发,但随访时间短,肾切除和膀胱切除术后复发结论不明确。

核心结论

  • 低级别证据表明,与其他血液保护技术相比,ICS降低异体输血率和成本,且不影响并发症。
  • ICS似乎不增加前列腺切除术后肿瘤复发,但随访时间短。
  • 由于研究规模小和随访短,无法对肾切除或膀胱切除术后复发作结论,需长期随访的随机试验。

研究设计与样本

  • 系统评价与荟萃分析,检索Medline、Embase和Cochrane Library至2017年8月,方法预先发布于PROSPERO。
  • 队列包括开放前列腺切除术(11项)、开放膀胱切除术(2项)或开放部分肾切除术(1项)。

主要发现

  • 荟萃分析仅在前列腺切除术研究中可行,ICS较无血液保护技术降低异体输血率(OR 0.34,95%CI 0.15-0.76)。
  • ICS与PAD相比异体输血率无显著差异(OR 0.76,95%CI 0.39-1.31)。
  • 非前列腺切除术中,ICS患者异体输血率在一项研究中显著更高,在两项研究中相似。
  • 肿瘤复发在两项研究中显著更少,八项研究中相似,四项研究未测量。
  • 所有六项报告并发症的研究均发现ICS队列无差异;一项1995年研究显示ICS比PAD更贵,两项较新研究显示ICS比无血液保护技术更便宜。

关键数值与推荐

  • 前列腺切除术中ICS vs 无血液保护技术:异体输血率OR 0.34(95%CI 0.15-0.76)。
  • 前列腺切除术中ICS vs PAD:异体输血率OR 0.76(95%CI 0.39-1.31)。
  • 因研究间异质性,复发、并发症和成本未能进行荟萃分析。

临床怎么用

  • 前列腺切除术中可考虑ICS以降低异体输血需求,但需权衡与PAD的无差异结果。
  • ICS未增加前列腺切除术后肿瘤复发,但随访短,需长期监测。
  • 肾切除和膀胱切除术后复发风险不明确,应个体化决策并优先参与随机试验。

局限性

  • 仅纳入观察性研究,证据级别低。
  • 研究规模小且随访时间短。
  • 研究间异质性大,复发、并发症和成本无法荟萃分析。
  • 仅前列腺切除术的异体输血率可进行荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate systematically the safety and efficacy of intra-operative cell salvage (ICS) in urology. METHODS: A search of Medline, Embase and Cochrane Library to August 2017 was performed using methods pre-published on PROSPERO. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. Eligible titles were comparative studies published in English that used ICS in urology. Primary outcomes were allogeneic transfusion rates (ATRs) and tumour recurrence. Secondary outcomes were complications and cost. RESULTS: Fourteen observational studies were identified, with a total of 4 536 patients. ICS was compared with no the blood conservation technique (seven studies), preoperative autologous donation (PAD; five studies) or both (two studies). Cohorts underwent open prostatectomy (11 studies), open cystectomy (two studies) or open partial nephrectomy (one study). Meta-analysis was possible only for ATRs within prostatectomy studies. In this setting, ICS reduced ATR compared with no the blood conservation technique (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.15-0.76) but not PAD (OR 0.76, 95% CI 0.39-1.31). In the non-prostatectomy setting, ATRs amongst patients who underwent ICS were significantly higher or similar in one and two studies, respectively. Tumour recurrence was found to be significantly less common (two studies), similar (eight studies) or not measured (four studies). All six studies reporting complications found no difference in their ICS cohorts. Regarding cost, one study from 1995 found ICS more expensive than PAD, while two more recent studies found ICS to be cheaper than no blood conservation technique. As a result of inter-study heterogeneity, meta-analyses were not possible for recurrence, complications or cost. CONCLUSION: Low-level evidence exists that, compared with other blood conservation techniques, ICS reduces ATR and cost while not affecting complications. It does not appear to increase tumour recurrence post-prostatectomy, although follow-up durations were short. Small study sizes and short follow-ups mean conclusions cannot be drawn with regard to recurrence after nephrectomy or cystectomy. Randomized trials with long-term follow-up evaluating ICS in urology are required.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kinnear N, O'Callaghan M, Hennessey D, et al. Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies. BJU Int. 2018. PMID: 29726092. doi:10.1111/bju.14373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。